EFFECTIVENESS OF ICOSAPENT ETHYL IN MIDDLE EASTERN PATIENTS WITH DYSLIPIDEMIA

被引：0
|
作者：
Odeh, Mohamed [1 ]
Afandi, Bachar [2 ]
机构：
[1] Sulaiman Al Habib Med Grp, Riyadh, Saudi Arabia
[2] Tawam Hosp, Abu Dhabi, U Arab Emirates
来源：
ATHEROSCLEROSIS | 2024年 / 399卷
关键词：
D O I：
10.1016/j.atherosclerosis.2024.118701
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Defining the Role of Icosapent Ethyl in Clinical Practice
    Subhankar Chatterjee
    Adrija Hajra
    Dhrubajyoti Bandyopadhyay
    Raktim K. Ghosh
    Prakash C. Deedwania
    American Journal of Cardiovascular Drugs, 2020, 20 : 517 - 524
  • [42] Defining the Role of Icosapent Ethyl in Clinical Practice
    Chatterjee, Subhankar
    Hajra, Adrija
    Bandyopadhyay, Dhrubajyoti
    Ghosh, Raktim K.
    Deedwania, Prakash C.
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2020, 20 (06) : 517 - 524
  • [43] Medicare Utilization and Associated Spending on Icosapent Ethyl
    Parajuli, Shreyash
    Majmundar, Vidit
    Pandey, Priya
    Raju, Arvindkumar Venkataramana
    Yukselen, Zeynep
    Hadley, Michelle
    CIRCULATION, 2024, 150
  • [44] Impact of Icosapent Ethyl on Cardiovascular Risk Recuction in Patients With Heart Failure in REDUCE-IT
    Selvaraj, Senthil
    Bhatt, Deepak L.
    Steg, Ph Gabriel
    Miller, Michael
    Brinton, Eliot A.
    Jacobson, Terry A.
    Juliano, Rebecca A.
    Jiao, Lixia
    Tardif, Jean-Claude
    Ballantyne, Christie M.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2022, 11 (07):
  • [45] Icosapent ethyl for dyslipidaemia in patients with diabetes and coronary artery disease: Act now to reduce it
    Lan, Nick S. R.
    Fegan, P. Gerry
    Yeap, Bu B.
    Rankin, James M.
    Watts, Gerald F.
    DIABETES OBESITY & METABOLISM, 2019, 21 (07): : 1734 - 1736
  • [46] COST-EFFECTIVENESS OF ICOSAPENT ETHYL (IPE) FOR THE REDUCTION OF THE RISK OF ISCHEMIC CARDIOVASCULAR EVENTS IN CANADA.
    Lachaine, J.
    Charron, J. N.
    Gregoire, J. C.
    Hegele, R. A.
    Leiter, L. A.
    VALUE IN HEALTH, 2020, 23 : S496 - S496
  • [47] Benefits of Icosapent Ethyl in Patients with Prior Peripheral Artery Disease: REDUCE-IT PAD
    Bhatt, Deepak L.
    Steg, Philippe G.
    Miller, Michael
    Brinton, Eliot A.
    Jacobson, Terry A.
    Tardif, Jean-Claude
    Ketchum, Steven
    Juliano, Rebecca
    Jiao, Lisa
    Copland, Christina
    Doyle, Ralph
    CIRCULATION, 2021, 144
  • [48] Substantial cardiovascular benefit from icosapent ethyl in patients with diabetes: REDUCE-IT DIABETES
    Bhatt, D.
    Brinton, E.
    Miller, M.
    Steg, P. G.
    Jacobson, T. A.
    Ketchum, S. B.
    Doyle, R. T.
    Juliano, R. A.
    Jiao, L.
    Granowitz, C.
    Ganda, O.
    Busch, R.
    Herrington, D.
    Tardif, J. -C.
    Ballantyne, C.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S302 - S303
  • [49] Catch of the Day: Icosapent Ethyl for Reducing Cardiovascular Risk
    Dixon, Dave L.
    AMERICAN JOURNAL OF MEDICINE, 2020, 133 (07): : 802 - 804
  • [50] Icosapent Ethyl: A Review of Its Use in Severe Hypertriglyceridemia
    Kim, Esther S.
    McCormack, Paul L.
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2014, 14 (06) : 471 - 478
12345